Emerg Infect Dis. 2022 Dec;28(13):S225-S231. doi: 10.3201/eid2813.220604.
The rapid rollout of vaccines against COVID-19 as a key mitigation strategy to end the global pandemic might be informed by lessons learned from rubella vaccine implementation in response to the global rubella epidemic of 1963-1965. That rubella epidemic led to the development of a rubella vaccine that has been introduced in all but 21 countries worldwide and has led to elimination of rubella in 93 countries. Although widespread introduction and use of rubella vaccines was slower than that for COVID-19 vaccines, the process can provide valuable insights for the continued battle against COVID-19. Experiences from the rubella disease control program highlight the critical and evolving elements of a vaccination program, including clearly delineated goals and strategies, regular data-driven revisions to the program based on disease and vaccine safety surveillance, and evaluations to identify the vaccine most capable of achieving disease control targets.
新冠疫苗的快速推出是结束全球大流行的关键缓解策略之一,这或许可以借鉴应对 1963-1965 年全球风疹疫情时实施风疹疫苗的经验教训。那场风疹疫情促使研发出了风疹疫苗,该疫苗已在全球除 21 个国家以外的所有国家推出,并已在 93 个国家消除了风疹。尽管风疹疫苗的广泛引入和使用速度比新冠疫苗慢,但这一过程可以为抗击新冠疫情提供宝贵的见解。风疹疾病控制项目的经验突出了疫苗接种项目的关键和不断发展的要素,包括明确的目标和策略、根据疾病和疫苗安全监测定期对项目进行数据驱动的修订,以及评估哪种疫苗最有能力实现疾病控制目标。